To Compare the Effects of Herbal Medicines With Traditional Allopathic Medicines in Cases of Patients With Metabolic Syndrome

NCT ID: NCT06515652

Last Updated: 2024-07-23

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-09-01
• Study Completion Date: 2024-08-30

Brief Summary

Metabolic syndrome is an important global public health problem and comprises a group of complex risk factors, including obesity, dyslipidemia, hyperglycemia, and hypertension. One of the main diagnostic components of metabolic syndrome is obesity, which is usually measured by the waist circumference and the intra-abdominal visceral fat, in addition to dyslipidemia (the condition of raised triglycerides and reduced high density lipoprotein (HDL)-cholesterol in blood; other components are raised blood pressure and fasting plasma glucose, all of which are related to weight gain.

Metabolic syndrome is related to cardio metabolic risk factors and lipid disorders. Worldwide, cardiovascular diseases (CVD) are the leading cause of mortality and morbidity. It is expected that by 2030, mortality from CVD will reach 22.5 million people, compared with 17.5 million deaths in 2012.

Major pharmacological interventions include management of dyslipidemia with statins, decreasing prothrombotic risk with antiplatelet drugs, and the use of insulin sensitizers to decrease the risk of diabetes. In addition to non-pharmacologic interventions that improve BP, pharmacological agents provide the primary basis for hypertension management in the majority of patients. Among major antihypertensive agents, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), and thiazide (or thiazide-like) diuretics are preferentially recommended in the general condition because of their additional cardiovascular protection effects and/or accessibility.

Herbal drugs are being used worldwide in the management of metabolic syndrome now a days. Some of the herbs e.g. Terminalia arjuna, Trigonella Foenum-graecum, Allium Sativum, Cinnamon verum and Zingiber Officinale are being used very effectively in managing metabolic syndrome.

METHODOLOGY:

The basic purpose of this study will be to explore a poly herbal combination for effective and safe management of metabolic syndrome. This is a multicenter; prospective study will be conducted in the department of Pharmacology, HCMD in collaboration with Hamdard University Hospital, National Medical Center and Amna Unani Hospital.

After fulfilling the inclusion and exclusion criteria a total of 200 patients will be enrolled and divided in 2 groups. One group will be given allopathic combination while the other group will be given a poly herbal formulation. Important parameters include BMI, Systolic and Diastolic blood pressure, lipid profile, HbA1c, S.creatinine, Urinary Albumin, Urinary Creatinine, ALT & AST. Follow up will be done at day 0, 30, 60 & 90th of treatment. The data will be recorded in a tabulated form and statistical analysis will be done at the end of the study to see the significance of the two studies.

Conditions

Metabolic Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Allopathic

1. Tablet.Rosuvastatin 10mg once daily for 3 months

2. Tablet. Telmisartan 40mg once daily for 3 months

3. Tablet. Sitagliptin / Metformin 50/500mg once daily for 3 months

Group Type: ACTIVE_COMPARATOR

rosuvastatin, METFORMIN, Sitagliptin, Telmisartan, Cinnamon. garlic, Ginger, Methi dana, Arjun

Intervention Type: DRUG

Comparing allopathic and herbal group of drugs for metabolic syndrome

Herbal

1. Cinammon powder 2 gm once daily for 3 months

2. Garlic powder 1 gm once daily for 3 months

3. Ginger powder 4 gm once daily for 3 months

4. Fenugreek powder 10 gm once daily for 3 months

5. Arjuna 2 gm once daily for 3 months

Group Type: ACTIVE_COMPARATOR

rosuvastatin, METFORMIN, Sitagliptin, Telmisartan, Cinnamon. garlic, Ginger, Methi dana, Arjun

Intervention Type: DRUG

Comparing allopathic and herbal group of drugs for metabolic syndrome

Interventions

rosuvastatin, METFORMIN, Sitagliptin, Telmisartan, Cinnamon. garlic, Ginger, Methi dana, Arjun

Comparing allopathic and herbal group of drugs for metabolic syndrome

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients ageing between 35-65 years;
• Patients with a diagnosis of metabolic syndrome according to the criteria of IDF 2005

Exclusion Criteria

• Pregnant & lactating female
• Use of insulin or sulfonamide derivative oral antidiabetic drugs
• Doing heavy physical activity or working in a physically demanding job
• Presence of liver or kidney disease, or immune deficiency
• Patients with history of myocardial infarction, coronary artery bypass surgery, unstable angina & cardiac failure.
• Conditions that will seriously affect weight management such as having had bariatric surgery
• Determined to have had an unintentional sudden weight loss of more than 5% in the last three months
• Intellectual disability or significant medical or psychiatric illness as documented by the referring doctor.
• Any contraindication to the use of drugs involved in the study

• Minimum Eligible Age: 35 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hamdard University

OTHER

Sponsor Role: lead

Responsible Party

SYEDA AMBER ZAIDI

Assitstant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Prof. Dr. M. Sajid Abbas Jaffri

Karachi, Sindh, Pakistan

Site Status: RECRUITING

Countries

Pakistan

Central Contacts

Syeda Amber Zaidi, MBBS MPhil

Role: CONTACT

amberzaidi36@gmail.com

03323188867

Syed Mohsin Turab, MBBS MPhil PhD

Role: CONTACT

mohsin.turab@hamdard.edu.pk

03332115515

Facility Contacts

Shiraz M Siddiqui, PhD

Role: primary

Other Identifiers

FHMS HamdardUniversity

Identifier Type: -

Identifier Source: org_study_id